RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2011; 31(3): 325-337
DOI: 10.1055/s-0031-1287654
© Thieme Medical PublishersDOI: 10.1055/s-0031-1287654
Role of Infection and Neurologic Dysfunction in Chronic Fatigue Syndrome
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
30. September 2011 (online)
ABSTRACT
Chronic fatiguing illnesses following well-documented infections and acute “infectious-like” illnesses of uncertain cause have been reported for many decades. Chronic fatigue syndrome (CFS) was first formally defined in 1988. There is considerable evidence that CFS is associated with abnormalities of the central and autonomic nervous systems. There also is evidence linking several infectious agents with CFS, although no agent has been proven to be a cause of the illness. Most of the infectious agents that have been linked to CFS are able to produce a persistent, often life-long, infection and thus are a constant incitement to the immune system. Most also have been shown to be neuropathogens. The evidence is consistent with the hypothesis that CFS, in some cases, can be triggered and perpetuated by several chronic infections that directly or indirectly affect the nervous system, and that symptoms are a reflection of the immune response to the infection.
KEYWORDS
Chronic fatigue syndrome - neuroendocrine - magnetic resonance imaging - central nervous system - autonomic nervous system - depression - immune activation - mitochondrial dysfunction - Epstein-Barr virus - human herpesvirus 6 - enterovirus
REFERENCES
- 1 Fukuda K, Straus S E, Hickie I, Sharpe M C, Dobbins J G, Komaroff A. International Chronic Fatigue Syndrome Study Group . The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994; 121 (12) 953-959
- 2 Reyes M, Nisenbaum R, Hoaglin D C et al.. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med. 2003; 163 (13) 1530-1536
- 3 Komaroff A L, Fagioli L R, Doolittle T H et al.. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med. 1996; 101 (3) 281-290
- 4 Reynolds K J, Vernon S D, Bouchery E, Reeves W C. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc. 2004; 2 (1) 4
- 5 Demitrack M A, Dale J K, Straus S E et al.. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab. 1991; 73 (6) 1224-1234
- 6 Dinan T G, Majeed T, Lavelle E, Scott L V, Berti C, Behan P. Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology. 1997; 22 (4) 261-267
- 7 Scott L V, Medbak S, Dinan T G. The low dose ACTH test in chronic fatigue syndrome and in health. Clin Endocrinol (Oxf). 1998; 48 (6) 733-737
- 8 Scott L V, Dinan T G. Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affect Disord. 1998; 47 (1-3) 49-54
- 9 Scott L V, Teh J, Reznek R, Martin A, Sohaib A, Dinan T G. Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study. Psychoneuroendocrinology. 1999; 24 (7) 759-768
- 10 Cleare A J, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fatigue syndrome. Am J Psychiatry. 2001; 158 (4) 641-643
- 11 Demitrack M A, Gold P W, Dale J K, Krahn D D, Kling M A, Straus S E. Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol Psychiatry. 1992; 32 (12) 1065-1077
- 12 Bakheit A MO, Behan P O, Dinan T G, Gray C E, O'Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ. 1992; 304 (6833) 1010-1012
- 13 Cleare A J, Bearn J, Allain T et al.. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord. 1995; 34 (4) 283-289
- 14 Moorkens G, Berwaerts J, Wynants H, Abs R. Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome. Clin Endocrinol (Oxf). 2000; 53 (1) 99-106
- 15 Patarca R. Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci. 2001; 933 185-200
- 16 Gupta S, Aggarwal S, Starr A. Increased production of interleukin-6 by adherent and non-adherent mononuclear cells during ‘natural fatigue’ but not following ‘experimental fatigue' in patients with chronic fatigue syndrome. Int J Mol Med. 1999; 3 (2) 209-213
- 17 Gupta S, Aggarwal S, See D M, Starr A. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res. 1997; 31 (1) 149-156
- 18 Vgontzas A N, Zoumakis M, Papanicolaou D A et al.. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism. 2002; 51 (7) 887-892
- 19 Buchwald D, Cheney P R, Peterson D L et al.. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med. 1992; 116 (2) 103-113
- 20 Schwartz R B, Garada B M, Komaroff A L et al.. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. AJR Am J Roentgenol. 1994; 162 (4) 935-941
- 21 Natelson B H, Cohen J M, Brassloff I, Lee H J. A controlled study of brain magnetic resonance imaging in patients with the chronic fatigue syndrome. J Neurol Sci. 1993; 120 (2) 213-217
- 22 Cook D B, Lange G, DeLuca J, Natelson B H. Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. Int J Neurosci. 2001; 107 (1-2) 1-6
- 23 Lange G, DeLuca J, Maldjian J A, Lee H-J, Tiersky L A, Natelson B H. Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome. J Neurol Sci. 1999; 171 (1) 3-7
- 24 Lange G, Holodny A I, DeLuca J et al.. Quantitative assessment of cerebral ventricular volumes in chronic fatigue syndrome. Appl Neuropsychol. 2001; 8 (1) 23-30
- 25 Okada T, Tanaka M, Kuratsune H, Watanabe Y, Sadato N. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. BMC Neurol. 2004; 4 14-19
- 26 de Lange F P, Kalkman J S, Bleijenberg G, Hagoort P, van der Meer J WM, Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage. 2005; 26 (3) 777-781
- 27 Perrin R, Embleton K, Pentreath V W, Jackson A. Longitudinal MRI shows no cerebral abnormality in chronic fatigue syndrome. Br J Radiol. 2010; 83 (989) 419-423
- 28 de Lange F P, Kalkman J S, Bleijenberg G et al.. Neural correlates of the chronic fatigue syndrome—an fMRI study. Brain. 2004; 127 (Pt 9) 1948-1957
- 29 Tanaka M, Sadato N, Okada T et al.. Reduced responsiveness is an essential feature of chronic fatigue syndrome: A fMRI study. BMC Neurol. 2006; 6 9-23
- 30 Caseras X, Mataix-Cols D, Giampietro V et al.. Probing the working memory system in chronic fatigue syndrome: a functional magnetic resonance imaging study using the n-back task. Psychosom Med. 2006; 68 (6) 947-955
- 31 Cook D B, O'Connor P J, Lange G, Steffener J. Functional neuroimaging correlates of mental fatigue induced by cognition among chronic fatigue syndrome patients and controls. Neuroimage. 2007; 36 (1) 108-122
- 32 Caseras X, Mataix-Cols D, Rimes K A et al.. The neural correlates of fatigue: an exploratory imaginal fatigue provocation study in chronic fatigue syndrome. Psychol Med. 2008; 38 (7) 941-951
- 33 Lange G, Steffener J, Cook D B et al.. Objective evidence of cognitive complaints in chronic fatigue syndrome: a BOLD fMRI study of verbal working memory. Neuroimage. 2005; 26 (2) 513-524
- 34 Brooks J CW, Roberts N, Whitehouse G, Majeed T. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol. 2000; 73 (875) 1206-1208
- 35 Puri B K, Counsell S J, Zaman R et al.. Relative increase in choline in the occipital cortex in chronic fatigue syndrome. Acta Psychiatr Scand. 2002; 106 (3) 224-226
- 36 Chaudhuri A, Condon B R, Gow J W, Brennan D, Hadley D M. Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. Neuroreport. 2003; 14 (2) 225-228
- 37 Ichise M, Salit I E, Abbey S E et al.. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. Nucl Med Commun. 1992; 13 (10) 767-772
- 38 Schwartz R B, Komaroff A L, Garada B M et al.. SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. AJR Am J Roentgenol. 1994; 162 (4) 943-951
- 39 Schmaling K B, Lewis D H, Fiedelak J I, Mahurin R, Buchwald D S. Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. Psychosom Med. 2003; 65 (1) 129-136
- 40 Fischler B, D'Haenen H, Cluydts R et al.. Comparison of 99m Tc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow. Neuropsychobiology. 1996; 34 (4) 175-183
- 41 Lewis D H, Mayberg H S, Fischer M E et al.. Monozygotic twins discordant for chronic fatigue syndrome: regional cerebral blood flow SPECT. Radiology. 2001; 219 (3) 766-773
- 42 Siessmeier T, Nix W A, Hardt J, Schreckenberger M, Egle U T, Bartenstein P. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2003; 74 (7) 922-928
- 43 Yamamoto S, Ouchi Y, Onoe H et al.. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport. 2004; 15 (17) 2571-2574
- 44 Tirelli U, Chierichetti F, Tavio M et al.. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med. 1998; 105 (3A) 54S-58S
- 45 Cleare A J, Messa C, Rabiner E A, Grasby P M. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. Biol Psychiatry. 2005; 57 (3) 239-246
- 46 Gordon R, Michalewski H J, Nguyen T, Gupta S, Starr A. Cortical motor potential alterations in chronic fatigue syndrome. Int J Mol Med. 1999; 4 (5) 493-499
- 47 Duffy F H, McAnulty G B, McCreary M C, Cuchural G J, Komaroff A L. EEG spectral coherence data distinguish chronic fatigue syndrome patients from healthy controls and depressed patients - A case control study. BMC Neurol. 2011; 11 (1) 82
- 48 Siemionow V, Fang Y, Calabrese L, Sahgal V, Yue G H. Altered central nervous system signal during motor performance in chronic fatigue syndrome. Clin Neurophysiol. 2004; 115 (10) 2372-2381
- 49 Natelson B H, Weaver S A, Tseng C-L, Ottenweller J E. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin Diagn Lab Immunol. 2005; 12 (1) 52-55
- 50 Mathew S J, Mao X, Keegan K A et al.. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009; 22 (3) 251-258
- 51 Murrough J W, Mao X, Collins K A et al.. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 2010; 23 (6) 643-650
- 52 Baraniuk J N, Casado B, Maibach H, Clauw D J, Pannell L K, Hess S. A chronic fatigue syndrome-related proteome in human cerebrospinal fluid. BMC Neurol. 2005; 5 22-40
- 53 Clauw D J. Perspectives on fatigue from the study of chronic fatigue syndrome and related conditions. PM R. 2010; 2 (5) 414-430
- 54 Johnson S K, DeLuca J, Fiedler N, Natelson B H. Cognitive functioning of patients with chronic fatigue syndrome. Clin Infect Dis. 1994; 18 (Suppl 1) S84-S85
- 55 Krupp L B, Sliwinski M, Masur D M, Friedberg F, Coyle P K. Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. Arch Neurol. 1994; 51 (7) 705-710
- 56 Marcel B, Komaroff A L, Fagioli L R, Kornish II R J, Albert M S. Cognitive deficits in patients with chronic fatigue syndrome. Biol Psychiatry. 1996; 40 (6) 535-541
- 57 Tiersky L A, Johnson S K, Lange G, Natelson B H, DeLuca J. Neuropsychology of chronic fatigue syndrome: a critical review. J Clin Exp Neuropsychol. 1997; 19 (4) 560-586
- 58 Daly E, Komaroff A L, Bloomingdale K, Wilson S, Albert M S. Neuropsychological function in patients with chronic fatigue syndrome, multiple sclerosis, and depression. Appl Neuropsychol. 2001; 8 (1) 12-22
- 59 Deluca J, Christodoulou C, Diamond B J, Rosenstein E D, Kramer N, Natelson B H. Working memory deficits in chronic fatigue syndrome: differentiating between speed and accuracy of information processing. J Int Neuropsychol Soc. 2004; 10 (1) 101-109
- 60 DeLuca J, Johnson S K, Natelson B H. Information processing efficiency in chronic fatigue syndrome and multiple sclerosis. Arch Neurol. 1993; 50 (3) 301-304
- 61 Sandman C A, Barron J L, Nackoul K, Goldstein J, Fidler F. Memory deficits associated with chronic fatigue immune dysfunction syndrome. Biol Psychiatry. 1993; 33 (8-9) 618-623
- 62 McDonald E, Cope H, David A. Cognitive impairment in patients with chronic fatigue: a preliminary study. J Neurol Neurosurg Psychiatry. 1993; 56 (7) 812-815
- 63 DeLuca J, Johnson S K, Natelson B H. Information processing efficiency in chronic fatigue syndrome and multiple sclerosis. Arch Neurol. 1993; 50 (3) 301-304
- 64 Schmaling K B, DiClementi J D, Cullum C M, Jones J F. Cognitive functioning in chronic fatigue syndrome and depression: a preliminary comparison. Psychosom Med. 1994; 56 (5) 383-388
- 65 DeLuca J, Johnson S K, Beldowicz D, Natelson B H. Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. J Neurol Neurosurg Psychiatry. 1995; 58 (1) 38-43
- 66 DeLuca J, Johnson S K, Ellis S P, Natelson B H. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. J Neurol Neurosurg Psychiatry. 1997; 62 (2) 151-155
- 67 Michiels V, Cluydts R, Fischler B. Attention and verbal learning in patients with chronic fatigue syndrome. J Int Neuropsychol Soc. 1998; 4 (5) 456-466
- 68 Cockshell S J, Mathias J L. Cognitive functioning in chronic fatigue syndrome: a meta-analysis. Psychol Med. 2010; 40 (8) 1253-1267
- 69 Constant E L, Adam S, Gillain B, Lambert M, Masquelier E, Seron X. Cognitive deficits in patients with chronic fatigue syndrome compared to those with major depressive disorder and healthy controls. Clin Neurol Neurosurg. 2011; 113 (4) 295-302
- 70 Sisto S A, Tapp W, Drastal S et al.. Vagal tone is reduced during paced breathing in patients with the chronic fatigue syndrome. Clin Auton Res. 1995; 5 (3) 139-143
- 71 Bou-Holaigah I, Rowe P C, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA. 1995; 274 (12) 961-967
- 72 Freeman R, Komaroff A L. Does the chronic fatigue syndrome involve the autonomic nervous system?. Am J Med. 1997; 102 (4) 357-364
- 73 Stewart J M, Gewitz M H, Weldon A, Arlievsky N, Li K, Munoz J. Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics. 1999; 103 (1) 116-121
- 74 Stewart J M. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res. 2000; 48 (2) 218-226
- 75 Naschitz J E, Sabo E, Naschitz S et al.. Hemodynamic instability in chronic fatigue syndrome: indices and diagnostic significance. Semin Arthritis Rheum. 2001; 31 (3) 199-208
- 76 Naschitz J E, Sabo E, Naschitz S et al.. Fractal analysis and recurrence quantification analysis of heart rate and pulse transit time for diagnosing chronic fatigue syndrome. Clin Auton Res. 2002; 12 (4) 264-272
- 77 Peckerman A, LaManca J J, Qureishi B et al.. Baroreceptor reflex and integrative stress responses in chronic fatigue syndrome. Psychosom Med. 2003; 65 (5) 889-895
- 78 Jones J F, Nicholson A, Nisenbaum R et al.. Orthostatic instability in a population-based study of chronic fatigue syndrome. Am J Med. 2005; 118 (12) 1415
- 79 Hollingsworth K G, Jones D E, Taylor R, Blamire A M, Newton J L. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Invest. 2010; 40 (7) 608-615
- 80 Biswal B, Kunwar P, Natelson B H. Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J Neurol Sci. 2011; 301 (1-2) 9-11
- 81 Gerrity T R, Bates J, Bell D S et al.. Chronic fatigue syndrome: what role does the autonomic nervous system play in the pathophysiology of this complex illness?. Neuroimmunomodulation. 2002-2003; 10 (3) 134-141
- 82 Newton J L, Okonkwo O, Sutcliffe K, Seth A, Shin J, Jones D EJ. Symptoms of autonomic dysfunction in chronic fatigue syndrome. QJM. 2007; 100 (8) 519-526
- 83 Taerk G S, Toner B B, Salit I E, Garfinkel P E, Ozersky S. Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis). Int J Psychiatry Med. 1987; 17 (1) 49-56
- 84 Kruesi M JP, Dale J, Straus S E. Psychiatric diagnoses in patients who have chronic fatigue syndrome. J Clin Psychiatry. 1989; 50 (2) 53-56
- 85 Wessely S, Powell R. Fatigue syndromes: a comparison of chronic “postviral” fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psychiatry. 1989; 52 (8) 940-948
- 86 Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry. 1990; 156 534-540
- 87 Gold D, Bowden R, Sixbey J et al.. Chronic fatigue. A prospective clinical and virologic study. JAMA. 1990; 264 (1) 48-53
- 88 Vercoulen JHMM, Swanink C MA, Zitman F G et al.. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet. 1996; 347 (9005) 858-861
- 89 Benjamin J E, Hoyt R C. Disability following postvaccinal (yellow fever) hepatitis. JAMA. 1945; 128 319-324
- 90 Imboden J B, Canter A, Cluff L E. Convalescence from influenza. A study of the psychological and clinical determinants. Arch Intern Med. 1961; 108 393-399
- 91 Lawton A H, Rich T A, McLendon S, Gates E H, Bond J O. Follow-up studies of St. Louis encephalitis in Florida: reevaluation of the emotional and health status of the survivors five years after acute illness. South Med J. 1970; 63 (1) 66-71
- 92 Rosene K A, Copass M K, Kastner L S, Nolan C M, Eschenbach D A. Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med. 1982; 96 (6 Pt 2) 865-870
- 93 Cluff L E, Trever R W, Imboden J B, Canter A. Brucellosis. II. Medical aspects of delayed convalescence. AMA Arch Intern Med. 1959; 103 (3) 398-405
- 94 Imboden J B, Canter A, Cluff L E, Trever R W. Brucellosis. III. Psychologic aspects of delayed convalescence. AMA Arch Intern Med. 1959; 103 (3) 406-414
- 95 Salit I E. Sporadic postinfectious neuromyasthenia. CMAJ. 1985; 133 (7) 659-663
- 96 Henderson D A, Shelokov A. Epidemic neuromyasthenia; clinical syndrome. N Engl J Med. 1959; 260 (15) 757-764
- 97 Hickie I, Davenport T, Wakefield D Dubbo Infection Outcomes Study Group et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006; 333 (7568) 575-578
- 98 Vollmer-Conna U, Fazou C, Cameron B et al.. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med. 2004; 34 (7) 1289-1297
- 99 Cameron B, Bharadwaj M, Burrows J Dubbo Infection Outcomes Study et al. Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load. J Infect Dis. 2006; 193 (5) 664-671
- 100 Vollmer-Conna U, Cameron B, Hadzi-Pavlovic D Dubbo Infective Outcomes Study Group et al. Postinfective fatigue syndrome is not associated with altered cytokine production. Clin Infect Dis. 2007; 45 (6) 732-735
- 101 Landay A L, Jessop C, Lennette E T, Levy J A. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet. 1991; 338 (8769) 707-712
- 102 Patarca R, Klimas N G, Lugtendorf S, Antoni M, Fletcher M A. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994; 18 (Suppl 1) S147-S153
- 103 Cannon J G, Angel J, Abad L et al.. Interleukin-1b, interleukin-1 receptor antagonist and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol. 1997; 17 (3) 253-261
- 104 Swanink C M, Vercoulen J H, Galama J M et al.. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis. 1996; 173 (2) 460-463
- 105 Bennett A L, Chao C C, Hu S et al.. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol. 1997; 17 (2) 160-166
- 106 Cannon J G, Angel J B, Ball R W, Abad L W, Fagioli L, Komaroff A L. Acute phase responses and cytokine secretion in chronic fatigue syndrome. J Clin Immunol. 1999; 19 (6) 414-421
- 107 Skowera A, Cleare A, Blair D, Bevis L, Wessely S C, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol. 2004; 135 (2) 294-302
- 108 Broderick G, Fuite J, Kreitz A, Vernon S D, Klimas N, Fletcher M A. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010; 24 (7) 1209-1217
- 109 Caligiuri M, Murray C, Buchwald D et al.. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987; 139 (10) 3306-3313
- 110 Aoki T, Usuda Y, Miyakoshi H, Tamura K, Herberman R B. Low natural killer syndrome: clinical and immunologic features. Nat Immun Cell Growth Regul. 1987; 6 (3) 116-128
- 111 Kibler R, Lucas D O, Hicks M J, Poulos B T, Jones J F. Immune function in chronic active Epstein-Barr virus infection. J Clin Immunol. 1985; 5 (1) 46-54
- 112 Klimas N G, Salvato F R, Morgan R, Fletcher M A. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990; 28 (6) 1403-1410
- 113 Whiteside T L, Herberman R B. The role of natural killer cells in human disease. Clin Immunol Immunopathol. 1989; 53 (1) 1-23
- 114 Suhadolnik R J, Reichenbach N L, Hitzges P et al.. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis. 1994; 18 (Suppl 1) S96-S104
- 115 Suhadolnik R J, Peterson D L, O'Brien K et al.. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res. 1997; 17 (7) 377-385
- 116 De Meirleir K, Bisbal C, Campine I et al.. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med. 2000; 108 (2) 99-105
- 117 Vernon S D, Unger E R, Dimulescu I M, Rajeevan M, Reeves W C. Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers. 2002; 18 (4) 193-199
- 118 Powell R, Ren J, Lewith G, Barclay W, Holgate S, Almond J. Identification of novel expressed sequences, up-regulated in the leucocytes of chronic fatigue syndrome patients. Clin Exp Allergy. 2003; 33 (10) 1450-1456
- 119 Steinau M, Unger E R, Vernon S D, Jones J F, Rajeevan M S. Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome. J Mol Med (Berl). 2004; 82 (11) 750-755
- 120 Kaushik N, Fear D, Richards S CM et al.. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol. 2005; 58 (8) 826-832
- 121 Vernon S D, Whistler T, Aslakson E, Rajeevan M, Reeves W C. Challenges for molecular profiling of chronic fatigue syndrome. Pharmacogenomics. 2006; 7 (2) 211-218
- 122 Gow J W, Hagan S, Herzyk P, Cannon C, Behan P O, Chaudhuri A. A gene signature for post-infectious chronic fatigue syndrome. BMC Med Genomics. 2009; 2 38
- 123 Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S, Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis. 1994; 18 (Suppl 1) S62-S67
- 124 Plioplys A V, Plioplys S. Electron-microscopic investigation of muscle mitochondria in chronic fatigue syndrome. Neuropsychobiology. 1995; 32 (4) 175-181
- 125 Edwards R HT, Gibson H, Clague J E, Helliwell T. Muscle histopathology and physiology in chronic fatigue syndrome. In: Bock G R, Whelan J, eds. Chronic Fatigue Syndrome. New York: Wiley; 1993: 102-131
- 126 Pietrangelo T, Mancinelli R, Toniolo L et al.. Transcription profile analysis of vastus lateralis muscle from patients with chronic fatigue syndrome. Int J Immunopathol Pharmacol. 2009; 22 (3) 795-807
- 127 Vernon S D, Whistler T, Cameron B, Hickie I B, Reeves W C, Lloyd A. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr Virus. BMC Infect Dis. 2006; 6 15-21
- 128 Robinson M, Gray S R, Watson M S et al.. Plasma IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue syndrome. Scand J Med Sci Sports. 2010; 20 (2) 282-290
- 129 Manuel y Keenoy B, Moorkens G, Vertommen J, De Leeuw I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci. 2001; 68 (17) 2037-2049
- 130 Pall M L. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypotheses. 2000; 54 (1) 115-125
- 131 Miwa K, Fujita M. Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome. Int J Cardiol. 2009; 136 (2) 238-239
- 132 Puri B K, Agour M, Gunatilake K DR, Fernando K AC, Gurusinghe A I, Treasaden I H. An in vivo proton neurospectroscopy study of cerebral oxidative stress in myalgic encephalomyelitis (chronic fatigue syndrome). Prostaglandins Leukot Essent Fatty Acids. 2009; 81 (5-6) 303-305
- 133 Miwa K, Fujita M. Fluctuation of serum vitamin E (alpha-tocopherol) concentrations during exacerbation and remission phases in patients with chronic fatigue syndrome. Heart Vessels. 2010; 25 (4) 319-323
- 134 Pall M L, Satterlee J D. Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder. Ann N Y Acad Sci. 2001; 933 323-329
- 135 Maes M, Mihaylova I, Kubera M, Bosmans E. Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuroendocrinol Lett. 2007; 28 (4) 463-469
- 136 Maes M, Mihaylova I, Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuroendocrinol Lett. 2007; 28 (4) 456-462
- 137 Suárez A, Guillamó E, Roig T et al.. Nitric oxide metabolite production during exercise in chronic fatigue syndrome: a case-control study. J Womens Health (Larchmt). 2010; 19 (6) 1073-1077
- 138 Light A R, White A T, Hughen R W, Light K C. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J Pain. 2009; 10 (10) 1099-1112
- 139 Van Oosterwijck J, Nijs J, Meeus M et al.. Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an experimental study. J Intern Med. 2010; 268 (3) 265-278
- 140 Manfredi A A, Rovere-Querini P. The mitochondrion—a Trojan horse that kicks off inflammation?. N Engl J Med. 2010; 362 (22) 2132-2134
- 141 Valyi-Nagy T, Dermody T S. Role of oxidative damage in the pathogenesis of viral infections of the nervous system. Histol Histopathol. 2005; 20 (3) 957-967
- 142 Isaacs R. Chronic infectious mononucleosis. Blood. 1948; 3 (8) 858-861
- 143 White P D, Thomas J M, Amess J et al.. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry. 1998; 173 475-481
- 144 Katon W, Russo J, Ashley R L, Buchwald D. Infectious mononucleosis: psychological symptoms during acute and subacute phases of illness. Gen Hosp Psychiatry. 1999; 21 (1) 21-29
- 145 Jones J F, Ray C G, Minnich L L, Hicks M J, Kibler R, Lucas D O. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med. 1985; 102 (1) 1-7
- 146 Straus S E, Tosato G, Armstrong G et al.. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med. 1985; 102 (1) 7-16
- 147 Salahuddin S Z, Ablashi D V, Markham P D et al.. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science. 1986; 234 (4776) 596-601
- 148 Josephs S F, Henry B, Balachandran N et al.. HHV-6 reactivation in chronic fatigue syndrome. Lancet. 1991; 337 (8753) 1346-1347
- 149 Secchiero P, Carrigan D R, Asano Y et al.. Detection of human herpesvirus 6 in plasma of children with primary infection and immunosuppressed patients by polymerase chain reaction. J Infect Dis. 1995; 171 (2) 273-280
- 150 Zorenzenon M, Rukh G, Botta G A et al.. Active HHV-6 infection in chronic fatigue syndrome patients from Italy: New data. J Chron Fatigue Syndr. 1996; 2 3-12
- 151 Patnaik M, Komaroff A L, Conley E, Ojo-Amaize E A, Peter J B. Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome. J Infect Dis. 1995; 172 (5) 1364-1367
- 152 Wagner M, Krueger G RF, Ablashi D V, Whitman J E. Chronic fatigue syndrome (CFS): a critical evaluation of testing for active human herpesvirus-6 (HHV-6) infection: review of data of 107 cases. J Chron Fatigue Syndr. 1996; 2 3-16
- 153 Ablashi D V, Eastman H B, Owen C B et al.. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol. 2000; 16 (3) 179-191
- 154 Nicolson G L, Gan R, Haier J. Multiple co-infections (mycoplasma, chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS. 2003; 111 (5) 557-566
- 155 Koelle D M, Barcy S, Huang M L et al.. Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. Clin Infect Dis. 2002; 35 (5) 518-525
- 156 Reeves W C, Stamey F R, Black J B, Mawle A C, Stewart J A, Pellett P E. Human herpesviruses 6 and 7 in chronic fatigue syndrome: a case-control study. Clin Infect Dis. 2000; 31 (1) 48-52
- 157 Yao K, Crawford J R, Komaroff A L, Ablashi D V, Jacobson S. Review part 2: Human herpesvirus-6 in central nervous system diseases. J Med Virol. 2010; 82 (10) 1669-1678
- 158 Flamand L, Gosselin J, D'Addario M et al.. Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol. 1991; 65 (9) 5105-5110
- 159 Enoki H, Takeda S, Matsubayashi R, Matsubayashi T. Steroid therapy in an infant with human herpesvirus 6 encephalopathy. Brain Dev. 2006; 28 (9) 597-599
- 160 Krueger G R, Guenther A, Knuefermann R et al.. Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6. In Vivo. 1994; 8 (4) 501-516
- 161 Arena A, Capozza A B, Di Luca D. Role of IFN gamma on TNF alpha, IL-1 beta and IL-6 release during HHV-6 infection. New Microbiol. 1996; 19 (3) 183-191
- 162 Go T, Nakamura K. Frequent seizures with elevated interleukin-6 at the eruptive stage of exanthema subitum. Eur J Paediatr Neurol. 2002; 6 (4) 221-223
- 163 Silverman R H, Nguyen C, Weight C J, Klein E A. The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol. 2010; 7 (7) 392-402
- 164 Lombardi V C, Ruscetti F W, Das Gupta J et al.. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science. 2009; 326 (5952) 585-589
- 165 Lo S-C, Pripuzova N, Li B et al.. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A. 2010; 107 (36) 15874-15879
- 166 Henrich T J, Li J Z, Felsenstein D et al.. Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis. 2010; 202 (10) 1478-1481
- 167 Knox K, Carrigan D, Simmons G et al.. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science. 2011; 333 (6038) 94-97
- 168 Shin C H, Bateman L, Schlaberg R et al.. Absence of XMRV and other MLV-related viruses in patients with chronic fatigue syndrome. J Virol. 2011; 85 7195-7202
- 169 Cunningham L, Bowles N E, Lane R JM, Dubowitz V, Archard L C. Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J Gen Virol. 1990; 71 (Pt 6) 1399-1402
- 170 Gow J W, Behan W MH, Clements G B, Woodall C, Riding M, Behan P O. Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. BMJ. 1991; 302 (6778) 692-696
- 171 Bowles N E, Bayston T A, Zhang H Y et al.. Persistence of enterovirus RNA in muscle biopsy samples suggests that some cases of chronic fatigue syndrome result from a previous, inflammatory viral myopathy. J Med. 1993; 24 (2-3) 145-160
- 172 Clements G B, McGarry F, Nairn C, Galbraith D N. Detection of enterovirus-specific RNA in serum: the relationship to chronic fatigue. J Med Virol. 1995; 45 (2) 156-161
- 173 Richardson J. Disturbance of hypothalamic function and evidence for persistent enteroviral infection in patients with chronic fatigue syndrome. J Chron Fatigue Syndr. 1995; 1 59-66
- 174 Soteriou B, Zhang H, Woodrow D R, Lane R JM, Archard L C. Identification of enteroviral RNA detected in muscle biopsies from patients with chronic fatigue syndrome of myositis, using reverse transcription-nested polymerase chain reaction and nucleotide sequencing. J Chron Fatigue Syndr. 1996; 2 74-75
- 175 Gow J W, Behan W MH, Cash P et al.. Enteroviral replication and chronic fatigue syndrome. J Chron Fatigue Syndr. 1996; 2 86
- 176 Chia J KS, Chia A Y. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol. 2008; 61 (1) 43-48
- 177 Swanink C MA, Melchers W JG, van der Meer J WM et al.. Enteroviruses and the chronic fatigue syndrome. Clin Infect Dis. 1994; 19 (5) 860-864
- 178 Lindh G, Samuelson A, Hedlund K O, Evengård B, Lindquist L, Ehrnst A. No findings of enteroviruses in Swedish patients with chronic fatigue syndrome. Scand J Infect Dis. 1996; 28 (3) 305-307
- 179 Kerr J R, Bracewell J, Laing I et al.. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol. 2002; 29 (3) 595-602
- 180 Kerr J R, Barah F, Mattey D L et al.. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol. 2001; 82 (Pt 12) 3011-3019
- 181 Matano S, Kinoshita H, Tanigawa K, Terahata S, Sugimoto T. Acute parvovirus B19 infection mimicking chronic fatigue syndrome. Intern Med. 2003; 42 (9) 903-905
- 182 Kerr J R, Gough J, Richards S CM et al.. Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Gen Virol. 2010; 91 (Pt 4) 893-897
- 183 Coyle P K, Krupp L. Borrelia burgdorferi infection in the chronic fatigue syndrome. Ann Neurol. 1990; 28 243-244
- 184 Sigal L H. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med. 1990; 88 (6) 577-581
- 185 Pollark R J, Komaroff A L, Telford III S R et al.. Borrelia burgdorferi infection is rarely found in patients with chronic fatigue syndrome. Clin Infect Dis. 1995; 20 (2) 467-468
- 186 Wildman M J, Smith E G, Groves J, Beattie J M, Caul E O, Ayres J G. Chronic fatigue following infection by Coxiella burnetii (Q fever): ten-year follow-up of the 1989 UK outbreak cohort. QJM. 2002; 95 (8) 527-538
- 187 Marmion B P, Sukocheva O, Storm P A et al.. Q fever: persistence of antigenic non-viable cell residues of Coxiella burnetii in the host—implications for post Q fever infection fatigue syndrome and other chronic sequelae. QJM. 2009; 102 (10) 673-684
- 188 Penttila I A, Harris R J, Storm P, Haynes D, Worswick D A, Marmion B P. Cytokine dysregulation in the post-Q-fever fatigue syndrome. QJM. 1998; 91 (8) 549-560
- 189 Schluederberg A, Straus S E, Peterson P et al.. NIH conference. Chronic fatigue syndrome research. Definition and medical outcome assessment. Ann Intern Med. 1992; 117 (4) 325-331
- 190 Bates D W, Buchwald D, Lee J et al.. Clinical laboratory test findings in patients with chronic fatigue syndrome. Arch Intern Med. 1995; 155 (1) 97-103
- 191 Chaudhuri A, Behan P O. Fatigue in neurological disorders. Lancet. 2004; 363 (9413) 978-988
- 192 Fox M D, Greicius M. Clinical applications of resting state functional connectivity. Front Syst Neurosci. 2010; 4 19
- 193 Wunder A, Klohs J, Dirnagl U. Non-invasive visualization of CNS inflammation with nuclear and optical imaging. Neuroscience. 2009; 158 (3) 1161-1173
- 194 de Backer M E, Nabuurs R J, van Buchem M A, van der Weerd L. MR-based molecular imaging of the brain: the next frontier. AJNR Am J Neuroradiol. 2010; 31 (9) 1577-1583
- 195 Modo M, Bulte J W. From molecules to man: the dawn of a vitreous man. Methods Mol Biol. 2011; 711 3-14
Anthony L KomaroffM.D.
Harvard Medical School, 10 Shattuck Street
2nd Floor, Boston, MA 02115
eMail: Komaroff@hms.harvard.edu